Maker of biologic products (nerve grafts, connectors, wraps) used by surgeons to repair damaged peripheral nerves.
Maker of biologic products (nerve grafts, connectors, wraps) used by surgeons to repair damaged peripheral nerves.
Sells directly to hospitals and surgery centres through its own sales force rather than distributors, and is paid per graft or connector used, so revenue follows the number of nerve-repair operations. The Avance graft, processed nerve tissue from human donors, is the larger product; Axoguard products wrap and protect a repaired nerve.
Moat: narrow (IP / patents, regulatory licence, brand). Category-leading, FDA-regulated processed nerve-graft products with limited direct biologic competitors.
Headquarters: Tampa, Florida · Founded: 1999 · Employees: 622
Size Axogen (AXGN) is a United States Health Care company (Medical Specialties) with a market value of $3.40B, the 1451st largest of 3,085 United States companies the cockpit tracks. Shares closed at $56.95 on 18 Nov 2026.
Performance Over six months the shares gained 33.4%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 24.3% over the last twelve months (peer median +5.7%); the operating margin is -5.2% (peer median 8.3%).
Valuation It trades at 87.3× forward earnings against a peer median of 25.1× (3rd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 53% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 17.7 points below its cost of capital (11.1% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $267M | $225M | $187M | $159M | $139M |
| Revenue growth | — | +20% | +18% | +15% | — |
| Gross profit | $198M | $167M | $142M | $128M | $114M |
| EBITDA | -$4.42M | $659,000 | $4.55M | -$15.9M | -$24.9M |
| Net income | -$31.9M | -$15.7M | -$9.96M | -$21.7M | -$28.9M |
| Free cash flow | $22.0M | -$2.93M | $1.43M | -$19.6M | -$36.1M |
| Capital expenditure | $8.34M | $5.59M | $4.52M | $14.9M | $21.3M |
| Total debt | $19.5M | $67.6M | $68.7M | $69.3M | $67.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Axogen AXGN | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% |
| Integra LifeSciences IART | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Baxter International BAX | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% |
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AXGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +57.5% | -0.2% | highest of 21 |
| 6-month return | +33.4% | +3.2% | 6th highest of 21 |
| Distance from 52-week high | -4.6% | -24.1% | 3rd highest of 21 |
| Revenue growth (TTM) | +24.3% | +5.7% | 5th highest of 21 |
| Operating margin | -5.2% | 8.3% | 4th lowest of 20 |
| Forward P/E | 87.3× | 25.1× | 3rd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 52.6% | 11.3% | 2nd most demanding of 17 |
| Growth delivered (Del g) | +14.9% | +8.5% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | +37.7 pp | +1.2 pp | 4th most demanding of 17 |
| ROIC minus cost of capital | -17.7 pp | -1.1 pp | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |